Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients

Area of Science:

• Ophthalmology
• Glaucoma Research
• Laser Therapy

Background:

• Open-angle glaucoma (OAG) and ocular hypertension require long-term management.
• Medical therapy is the standard treatment, but can have side effects and adherence issues.
• Selective laser trabeculoplasty (SLT) is a laser procedure targeting the eye's drainage system.

Purpose of the Study:

• To evaluate selective laser trabeculoplasty (SLT) as a replacement for medication in patients with medically controlled OAG or ocular hypertension.
• To assess the efficacy of SLT in reducing medication burden while maintaining target intraocular pressure (IOP).

Main Methods:

• A prospective randomized controlled trial involving 143 glaucoma patients.
• Patients were randomized to receive SLT or continue with medical therapy.
• Intraocular pressure (IOP) and medication count were monitored for 18 months post-treatment.

Main Results:

• SLT significantly reduced the mean number of medications from 1.5 to 0.29 after 18 months.
• 95% of eyes achieved >20% IOP reduction, and 86% achieved >30% IOP reduction after 18 months.
• 77% of patients no longer required medication 18 months after SLT, while maintaining target IOP.

Conclusions:

• Selective laser trabeculoplasty (SLT) is effective in reducing medication dependence for glaucoma patients.
• SLT can serve as a viable replacement therapy, maintaining IOP control and potentially minimizing side effects and adherence problems.
• This approach offers a promising alternative to long-term medical management in select glaucoma patients.